Abstract Number: 2511 • 2014 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
Background/Purpose: Remission is considered an achievable goal for many patients under biologic therapies. However, currently there is limited information about predictors of discontinuation of biologic…Abstract Number: 2510 • 2014 ACR/ARHP Annual Meeting
Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: To achieve comprehensive disease control (CDC; defined as simultaneous achievement of DAS28 < 3.2, HAQ-DI < 0.5 and ΔmTSS ≤ 0.5) or comprehensive disease…Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…Abstract Number: 2477 • 2014 ACR/ARHP Annual Meeting
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).…Abstract Number: 2475 • 2014 ACR/ARHP Annual Meeting
Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
Background/Purpose Use of imputed or observed data, as well as the patient (pt) population evaluated (eg. intention-to-treat [ITT], completer), affects the interpretation of long-term efficacy…Abstract Number: 2474 • 2014 ACR/ARHP Annual Meeting
Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study
Background/Purpose: Methotrexate (MTX) monotherapy or MTX in combination with other conventional and biologic disease-modifying antirheumatic drugs (DMARDs) is standard treatment for patients with inflammatory arthritis.…Abstract Number: 2473 • 2014 ACR/ARHP Annual Meeting
Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis
Background/Purpose: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin, and it is widely administered following organ transplantation. TAC…Abstract Number: 2492 • 2014 ACR/ARHP Annual Meeting
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
Background/Purpose: In RA, reduced efficacy with anti-TNF therapy1 and dose escalation2 have been reported for obese patients (pts) compared with non-obese pts. Clinical trials have…Abstract Number: 2491 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
Background/Purpose: To identify prognostic factors of retention for abatacept (ABA) treatment in patients (pts) with moderate-to-severe RA, using final results from the real-world ACTION study.…Abstract Number: 2490 • 2014 ACR/ARHP Annual Meeting
Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR)
Background/Purpose: Previous studies1-2 suggest the structural benefit of IV abatacept in patients with RA who have previously failed MTX, TNF therapy or both. Objectives:This study…Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
ACR Meeting Abstracts